You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

646 Results
Regimen
Cancer Type:
Head and Neck, 
Squamous Cell
Show More Show more tags
, Show Less Show fewer tags
Intent: Neoadjuvant, Curative
Drugs Used:
pembrolizumab (Unfunded)
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Sep 2025
Regimen
Cancer Type:
Head and Neck, 
Squamous Cell
Show More Show more tags
, Show Less Show fewer tags
Intent: Adjuvant, Curative
Drugs Used:
pembrolizumab (Unfunded)
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Sep 2025
Regimen
Cancer Type:
Head and Neck, 
Squamous Cell
Show More Show more tags
, Show Less Show fewer tags
Intent: Adjuvant, Curative
Drugs Used:
pembrolizumab (Unfunded)
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Oct 2025
Guidelines and Advice
Status: Current
ID: GL 1-25
Version: N/A
Mar 2023
Regimen
Cancer Type:
Gastrointestinal, 
Colorectal, 
Small bowel and appendix
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
New Drug Funding Program
    Panitumumab - In Combination with Chemotherapy for Metastatic Colorectal, Small Bowel, or Appendiceal Cancer
New Drug Funding Program
    Panitumumab - First-Line Treatment for Left-Sided Metastatic Colorectal Cancer
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
PANitumumab,
irinotecan,
leucovorin,
fluorouracil
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Updated
Dec 2025

Pages